113 related articles for article (PubMed ID: 36628904)
1. Quality of life after treatment with immune checkpoint inhibitors for lung cancer; the impact of age.
Suazo-Zepeda E; Vinke PC; Heuvelmans MA; Sidorenkov G; Hiltermann TJN; de Bock GH
Lung Cancer; 2023 Feb; 176():89-97. PubMed ID: 36628904
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life and its influencing factors among lung cancer patients receiving immune checkpoint inhibitors: A cross-sectional study.
Wang H; Dong Y; Fan T; Zhu S; Zhou Y; Song Y; Pan S; Wu Q; Li Y; Han Y
Eur J Oncol Nurs; 2024 Feb; 68():102507. PubMed ID: 38219475
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study.
Cotté FE; Voillot P; Bennett B; Falissard B; Tzourio C; Foulquié P; Gaudin AF; Lemasson H; Grumberg V; McDonald L; Faviez C; Schück S
J Med Internet Res; 2020 Sep; 22(9):e19694. PubMed ID: 32915159
[TBL] [Abstract][Full Text] [Related]
6. The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.
de Mol M; Visser S; Aerts J; Lodder P; van Walree N; Belderbos H; den Oudsten B
BMC Cancer; 2020 May; 20(1):431. PubMed ID: 32423432
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
[TBL] [Abstract][Full Text] [Related]
9. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
[TBL] [Abstract][Full Text] [Related]
10. Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
Van der Weijst L; Aguado-Barrera ME; Azria D; Berkovic P; Boisselier P; Briers E; Bultijnck R; Calvo-Crespo P; Chang-Claude J; Choudhury A; Defraene G; Demontois S; Dunning AM; Elliott RM; Ennis D; Faivre-Finn C; Franceschini M; Gutiérrez-Enríquez S; Herskind C; Higginson DS; Kerns SL; Johnson K; Mollà M; Lambrecht M; Ramos M; Rancati T; Rimner A; Rosenstein BS; De Ruysscher D; Salem A; Sangalli C; Seibold P; Sosa-Fajardo P; Sperk E; Stobart H; Summersgill H; Surmont V; Symonds P; Taboada-Lorenzo B; Talbot CJ; Valdagni R; Vega A; Veldeman L; Veldwijk MR; Ward T; Webb A; West CML; ; Lievens Y
Lung Cancer; 2022 Apr; 166():228-241. PubMed ID: 35334417
[TBL] [Abstract][Full Text] [Related]
11. Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer.
Marschner N; Zacharias S; Lordick F; Hegewisch-Becker S; Martens U; Welt A; Hagen V; Gleiber W; Bohnet S; Kruggel L; Dille S; Nusch A; Dörfel S; Decker T; Jänicke M
JAMA Netw Open; 2020 Mar; 3(3):e200643. PubMed ID: 32154886
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes and experiences from a prospective cohort study of older patients with cancer on checkpoint inhibitors: The ELDERS study.
Gomes F; Khatoon B; Sawyer C; Punnett G; Farrington N; Yorke J
J Geriatr Oncol; 2024 Jun; 15(5):101777. PubMed ID: 38704912
[TBL] [Abstract][Full Text] [Related]
13. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
Korde R; Veluswamy R; Allaire JC; Barnes G
Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
[TBL] [Abstract][Full Text] [Related]
14. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
Schulz TU; Zierold S; Sachse MM; Pesch G; Tomsitz D; Schilbach K; Kähler KC; French LE; Heinzerling L
Eur J Cancer; 2022 Nov; 176():88-99. PubMed ID: 36198246
[TBL] [Abstract][Full Text] [Related]
15. Frailty is associated with decline in health-related quality of life of patients treated for head and neck cancer.
de Vries J; Bras L; Sidorenkov G; Festen S; Steenbakkers RJHM; Langendijk JA; Witjes MJH; van der Laan BFAM; de Bock GH; Halmos GB
Oral Oncol; 2020 Dec; 111():105020. PubMed ID: 33045628
[TBL] [Abstract][Full Text] [Related]
16. Associations between age and patient-reported outcomes, emergency department visits, and hospitalizations among lung cancer patients receiving immune checkpoint inhibitors.
Fleszar-Pavlovic SE; Natori A; Moreno PI; Medina HN; Sookdeo V; MacIntyre J; Penedo FJ
Psychooncology; 2024 Jan; 33(1):e6293. PubMed ID: 38282219
[TBL] [Abstract][Full Text] [Related]
17. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
18. The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients.
Quinten C; Coens C; Ghislain I; Zikos E; Sprangers MA; Ringash J; Martinelli F; Ediebah DE; Maringwa J; Reeve BB; Greimel E; King MT; Bjordal K; Flechtner HH; Schmucker-Von Koch J; Taphoorn MJ; Weis J; Wildiers H; Velikova G; Bottomley A; ;
Eur J Cancer; 2015 Dec; 51(18):2808-19. PubMed ID: 26602015
[TBL] [Abstract][Full Text] [Related]
19. Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations.
Wilczynski O; Boisbouvier A; Radoszycki L; Cotté FE; Gaudin AF; Lemasson H
J Med Internet Res; 2022 Jan; 24(1):e25792. PubMed ID: 35014969
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
